RxDoctor Payments Data

Phi Tran, MD

Family Medicine · Lawrence, MANPI 1124092929

Payments from drug & device makers

$2,953in general payments, 2019–2025

Across 112 payments — averaging $26.36 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$2K
  • Otsuka America Pharmaceutical, Inc.$346
  • Novo Nordisk$202
  • Amgen$161
  • Amarin Pharma, Inc.$158
  • Gilead$142
  • plus $237 from 6 others

What the payments were for

  • Food & beverage$2,87097%
  • Education$833%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,953 in reported general payments places this provider in the 90th percentile of 1,049 family medicine providers in Massachusetts.

See all family medicine providers in Massachusetts

Medicare billing

Part B allowed, 2024
$20,776
Medicare patients
87
Services billed
248

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
TrulicityDulaglutide332$486,707
FarxigaDapagliflozin Propanediol243$245,563
JardianceEmpagliflozin248$237,840
EliquisApixaban145$114,001
JanuviaSitagliptin Phosphate78$77,544
VemlidyTenofovir Alafenamide25$35,818
Entecavir65$27,387
Albuterol Sulfate HfaAlbuterol Sulfate620$18,542
Trelegy ElliptaFluticasone/Umeclidin/Vilanter22$18,339
Fluticasone Propionate762$17,100
MyrbetriqMirabegron22$13,529
Combivent RespimatIpratropium/Albuterol Sulfate25$13,208
Atorvastatin Calcium1,325$13,005
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr28$13,004
Qvar RedihalerBeclomethasone Dipropionate33$10,259

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCTrulicity$53$486,707332 claims
Boehringer IngelheimJardiance, Combivent Respimat, Spiriva Respimat, Tradjenta$50$268,799301 claims
AstraZenecaFarxiga$1,707$245,563243 claims
PfizerEliquis$17$114,001145 claims
GileadVemlidy$142$35,81825 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,049 family medicine providers in Massachusetts.

Other family medicine in Lawrence

See the full list for Massachusetts

Where these figures come from

Is this you, or does something look wrong? →